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 ABSTRACT  
Emtricitabine (trade name: Emtriva) is an anti-HIV prevention and treatment drug. Emtricitabine 
(EMT) is used along with Tenofovir to form the combination-drug, Truvada, which is extremely 
effective in the prevention and treatment of HIV. Emtricitabine works by inhibiting reverse 
transcriptase and is conventionally administered orally in a tablet. Only one solid form 
corresponding to the pure drug is currently known. Cocrystallization is a method of creating 
novel solid forms by combining two or more components. In this context, cocrystallization is a 
good strategy to generate new and enhanced solid forms of Emtricitabine. Through our work 
with Emtricitabine, we generated new cocrystals with bipyridines using mechanochemical 
techniques. The new solids were studied and characterized using X-ray diffraction techniques 
such as powder X-ray diffraction and single crystal X-ray diffraction. We anticipate our work 
could lead to the design of improved solids of Emtricitabine that could be used in new 
administration routes of the drug.  
  
 INTRODUCTION: 
Emtricitabine (EMT) is a nucleoside reverse transcriptase inhibitor that inhibits the viral 
replication of HIV. It is used in a combination therapy as a treatment for patients with HIV. 
Emtricitabine is also used in combination with tenofovir as a HIV viral replication preventative 
drug: Truvada1. In this combination, EMT is listed in the WHO Model List of Essential 
Medicines as one of the most important medicines needed to treat the needs of patients globally2. 
EMT, along with most prescribed drugs, are most commonly administered orally3. In our 
research, we aimed to find different solid forms of Emtricitabine with improved chemical and 
physical properties.  
In order to do this, we utilized crystal engineering, a field that employs known non-
covalent interactions (supramolecular chemistry) and their properties in order to develop new 
solids. One strategy of crystal engineering is cocrystallization. 
 
Figure 1. Example of the different strategies to obtain new solid forms of drugs4. 
 
Cocrystallization is the process where two or more molecules interact with eachother 
through non-covalent interactions in a crystal lattice. One of the ways to promote 
 cocrystallization is through mechanochemistry through liquid assisted grinding (LAG). 
Mechanochemistry is a technique where solids are ground together, and the mechanical energy 
promotes reactions between the different molecules5. This is a green chemistry technique 
because a minimal amount of solvent is used.  
We used mechanochemistry in order to generate new solid forms of EMT improved 
chemical and physical properties. These new properties could lower the cost of production and 
enhance effectiveness. Other possibilities are new routes of administration for the drug: such as 
topically. Our research involving the cocrystallization of EMT also gives us an idea of how the 
drug interacts with other solid forms. Since EMT is typically used in combination therapies, this 
information could be applied in the future to predict interactions and to create solids of the EMT 
with improved physicochemical properties. This could improve the function of EMT in its role to 
prevent and treat HIV infection.  
Cocrystallization has been successful in the endeavor of improving a drug’s function 
before. For example, Entresto was the first cocrystal approved by the FDA. Entresto is a drug 
used in the treatment of heart disease. It is a combination of sacubitril and valsartan6. 
We report in this thesis, four novel cocrystals of EMT with bipyridines: 4’4-bipyridine 
(bpy), 1,2- bis(4-pyridyl)ethane (bpeta), 4,4′-azopyridine (apy), and 1,2-bis(4-pyridyl)ethene 
(bpe) (Scheme 1).  
  
Scheme 1: The molecular structures of EMT and bipyridines.  
 
Specifically, we modulated hydrogen bondings and π-π interactions in order to stabilize 
and form crystalline structures. The cocrystals self-assembled in either cleft conformation (bpeta, 
bpe and apy) or in catemer conformation (bpy) (Scheme 2).  
 
Scheme 2: The prior known EMT solid state conformation and the two novel conformations.  
 
 EXPERIMENTAL: 
Grinding Experiment: All chemicals were used as received from the vendors. EMT was 
purchased from Combi Blocks, while bpe, bpy, bpeta and apy were purchased from Aldrich.  
Cocrystals (EMT)2·(bpeta), (EMT)2·(bpe) and (EMT)2·(apy) were obtained by combining 
EMT (40 mg, 0.162 mmol) with the corresponding bipyridine (0.081 mmol) through liquid-
assisted grinding (LAG, methanol). Cocrystal (EMT)2·(bpy)2·H2O was obtained by combining 
EMT (40 mg, 0.162 mmol) with 4,4’-bipyridyl (25.3 mg, 0.162 mmol). Once grinding was 
completed, we took the powder and analyzed it to verify product formation using Powder X-Ray 
Diffraction. 
 
Powder X-Ray Diffraction (PXRD): The samples were transferred, in powder form, 
from the mortar-and-pestle to a glass slide for PXRD. PXRD information was collected using a 
Bruker D-8 ADVANCE X-ray diffractometer with Cu Kα radiation (λ = 1.54056 Å) and a 
LynxEye detector. Samples were collected from 5° to 35° 2θ (count time: fast continuous PSD, 
step size: 0.019°). The machine was operated at 40 kV and 30 mA, and data was acquired at 
room temperature. 
 
Cocrystal Synthesis: Our samples, still in powdered form, were dissolved in minimal 
methanol purchased from Aldrich. 2(EMT)·(bpeta), 2(EMT)·(apy), (EMT)·(bpy) and 
2(EMT)·(bpe) were each dissolved in separate vials, heated to a boil to ensure complete 
dissolution and then left to slowly evaporate at room temperature. As the solvent evaporated 
away the crystals formed. The resulting crystals were analyzed using Single Crystal X-Ray 
Diffraction.  
  
Single Crystal X-ray Diffraction (SCXRD): Data for 2(EMT)·(bpeta), 2(EMT)·(apy), 
(EMT)·(bpy) and 2(EMT)·(bpe) was measured on a Bruker D-8 Venture diffractometer equipped 
with a Duo-Photon 3 area detector using Mo-Kα radiation (λMoKα = 0.71073 Å, diffraction 
source: Incoatec micro-source 3.0 Mo). The frames were integrated with the Bruker SAINT 
software package using a narrow-frame algorithm. Data were corrected for absorption effects 
using the Multi-Scan method (SADABS). Structure solution, refinement and data output were 
carried out with the Olex2 software package. Programs from the Olex2 software package were 
then used in data reduction. Structure and arrangement solutions were then determined using 
ShelXL and ShelXT from the Olex2 graphical user interface. Data was then solved and refined 
using the Olex2 interface. All non-hydrogen atoms were refined using anisotropic displacement 
parameters. Illustrations of SCXRD data were made using MERCURY. In order to confirm our 
datathe formation of new solids and stoichiometries of single crystals, spectra of the cocrystals 
were collected using 1H NMR spectroscopy and IR spectroscopies.  
 
NMR: 1H NMR data was collected using a Bruker AVANCE 300 NMR spectrometer 
operating at 300 MHz using DMSO- d6 as the solvent. Signal assignment for EMT was based on 
previous reports and all data was processed with Mnova suite7.  
 
IR: Data was collected using a Thermo Scientific Nicolet 380 FT-IR spectrometer and 
measured in the range of 3600-750 cm−1. The FT-IR spectrometer equipped with a diamond 
ATR crystal. 
 
 RESULTS AND DISCUSSION 
When we began our research, the only known solid form of EMT was a dimer with 
itself8. Molecules of EMT were bonded together forming a dimer (Figure 2a, b) with hydrogen 
bonds. The nitrogen atoms acted as donors while the NH and OH groups acted as acceptors 
(Figure 2c) as depicted below in Figure 2.   
 
Figure 2: (a) Crystal structure of commercially available EMT, (b) dimer formation, and (c) crystal 
packing of EMT. 
 
Our experiment involved the combination of bipyridines and EMT. We combined each of 
the solid bipyridines with solid EMT in a mortar-and-pestle. In order to promote the formation of 
a new solid phase, we applied mechanochemistry for fifteen minutes using a drop of methanol as 
a solvent. The resulting solid was then dissolved into methanol, heated and left to evaporate. The 
results, after two days of slow evaporation, were crystals suitable for SCXRD.  
The product resulting from the EMT and bpeta combination, 2(EMT)·(bpeta), self-
assembled as discrete assemblies or, as we refer to it, in supramolecular clefts. This means that 
 the molecular structure resembles purely organic covalent molecular clefts from Rebek’s clefts 
(Figure 3)9.  
 
Figure 3: Conformation of the cleft geometry, Rebek’s covalent cleft on the left and our novel 
supramolecular cleft on the right.  
 
In order to create these supramolecular clefts, we first had to utilize liquid assisted 
grinding in order to promote the formation of a new solid phase. We analyzed the resulting 
powder using PXRD in order to confirm the formation of a new solid form. In the cocrystal 
pattern, some starting material peaks are visible in addition to novel peaks which are shown in 
Figure 4. 
 Figure 4: The PXRD patterns of the starting materials and the cocrystals. 
 
The appearance of novel peaks confirmed we had a new solid phase and in order to 
further analyze the structure, we used to use SCXRD. In order to employ this method, we needed 
to grow suitable single crystals via slow evaporation of a methanol solution with the powder 
completely dissolved.   
SCXRD revealed that, in order to form our supramolecular cleft, two EMT molecules 
interact with the bpeta bipyridine through O-H···N hydrogen bonds. The two EMT molecules 
self-assembled forming a dimer through N-H···N hydrogen bonds. Additional π-π interactions 
stabilize the supramolecular cleft. Collectively, the result of these interactions is that the two 
EMT molecules cradle the bipyridine between them. This is illustrated in Figure 5a below. The 
extended view of the crystal structure in Figure 5b shows a supramolecular sheet in the bc plane, 
composed of the EMT from our cocrystals. The π-π stabilization interactions of the 
supramolecular columns in the ac plane are depicted in Figure 5c.  
  
Figure 5: a) The crystal structure of 2(EMT)∙bpeta and b) extended packing into layers and c) columns.  
 
The supramolecular cleft defined above is tolerant to multiple bipyridines of similar 
dimensions. In addition to 2(EMT)·(bpeta): the crystal structure of 2(EMT)·(apy), and 
2(EMT)·(bpe) both self-assembled in the same supramolecular cleft conformations, as shown in 
Figure 6a and 6b below. The cleft similarities are emphasized by an overlay of the cocrystal 
structures in Figure 6c.  
  
 
Figure 6: The structures of cocrystals containing bpe and apy and the overlay of the clefts. 
 
A simplistic representation of the crystalline arrangement highlighting the O-H···N bond 
and the N···N and O···O distances, is shown in Figure 7 below. The bond distances for these 
interactions are listed in Table 1 below.  
 
  
Figure 7: Illustrates the hydrogen bonds and metrics detailed in Table 1 below.  
 
 
Table 1: The hydrogen bond lengths and metrics.  
 
The stoichiometry of the cocrystals was confirmed using 1H NMR spectroscopy. The 
spectra obtained from the single crystals provided evidence that the single crystals had two 
components: EMT and bipyridine. This is depicted below in Figure 8. 
  
Figure 8: The 1H NMR spectra of the cocrystal products and EMT. 
 
We confirmed the formation of a new solid form through IR spectroscopy using an ATR 
probe for solids. Formation of cocrystal was accompanied by a change in IR bands 
corresponding to O-H and N-H bonds. This change in signal reaffirmed the formation of novel 
solid phases. See appendix for spectra.  
In order to obtain new solid form with bpy, we employed liquid assisted grinding and 
analyzed the resulting powder using PXRD. Once again, novel peaks were observed confirming 
the formation of a new solid phase. These patterns are shown below, in Figure 9. 
  
Figure 9: The PXRD pattern of (EMT)·(bpy) cocrystal and starting materials. 
 
While apy, bpeta and bpe all formed similar cocrystal structures in combination with 
EMT, (EMT)·(bpy), on the other hand, self-assembles into a completely different formation. Bpy 
has a smaller molecular structure and shorter N···N distances. When this shorter conformer was 
used, we observed the formation of catemers supported by π-π interactions and hydrogen 
bonding.  
In the catemer structure, as opposed to the cleft where two EMT molecules cradle the 
bipyridine between them, the molecules form infinite π-π stacks. The EMT molecules in these 
stacks have a transoid conformation. This means the OH groups on the EMT are oriented 
opposite to each other as opposed to in the cisoid conformation observed in the supramolecular 
cleft. 
After confirming the formation of a new solid phase, we employed slow evaporation of 
methanol to obtain single crystals suitable for use in SCXRD. Crystallographic analysis revealed 
the components assembled in the infinite stack formation discussed above. In addition to π-π 
 stacking, a water molecule was identified to support the formation through hydrogen bonds. The 
cocrystal structure is displayed in Figure 10. 
 
 
Figure 10: The (EMT)·(bpy) cocrystal structure. 
 
In order to confirm the stoichiometry of the cocrystal, we used 1H NMR spectroscopy. 
Additionally, in order to confirm the formation of a new solid phase we utilized IR spectroscopy. 
The bands of the cocrystal changed intensity and frequency which is in agreement with the 
formation of a novel solid form.  
 
 
 
 
 
 
 
 
 
 
 CONCLUSIONS 
Through our research we learned that we can form cocrystals with EMT and various 
bipyridines. Long bipyridines of the same molecular size will result in formation of similar 
conformations. In this case our similar sized bipyridines formed a supramolecular cleft. While 
when a shorter bipyridine was used as a conformer, the assembly of the components shifted to 
accommodate the change in size and a catemer formation was observed supported by π-π 
stacking. In the future, we anticipate this research opening doors to create topical administrations 
of EMT and ultimately the creation of a HIV prevention patch.   
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 APPENDIX 
Crystal Data and Structural Refinement Tables 
Table 2: Crystal data and structure refinement for EMT-apy. 
Identification code EMT-apy 
Empirical formula C26H27F2N10O6S2 
Formula weight 677.69 
Temperature/K 296.15 
Crystal system monoclinic 
Space group P21 
a/Å 7.5024(8) 
b/Å 11.2194(11) 
c/Å 18.2134(18) 
α/° 90 
β/° 100.538(5) 
γ/° 90 
Volume/Å3 1507.2(3) 
Z 2 
ρcalcg/cm3 1.493 
μ/mm-1 0.249 
F(000) 702.0 
Crystal size/mm3 0.13 × 0.095 × 0.02 
Radiation MoKα (λ = 0.71073) 
2Θ range for data collection/° 4.55 to 55.786 
Index ranges 
-9 ≤ h ≤ 9, -14 ≤ k ≤ 14, -23 ≤ 
l ≤ 23 
Reflections collected 32670 
Independent reflections 7064 [Rint = 0.0428, Rsigma = 0.0350] 
Data/restraints/parameters 7064/6/424 
Goodness-of-fit on F2 1.073 
Final R indexes [I>=2σ (I)] R1 = 0.0487, wR2 = 0.1106 
Final R indexes [all data] R1 = 0.0591, wR2 = 0.1157 
Largest diff. peak/hole / e Å-3 0.48/-0.22 
Flack parameter 0.04(2) 
 
 
  
Table 3: Crystal data and structure refinement for EMT-bpy. 
Identification code EMT-bpy 
Empirical formula C36H38F2N10O7S2 
Formula weight 824.895 
Temperature/K 150.15 
Crystal system monoclinic 
Space group P21 
a/Å 7.4668(10) 
b/Å 9.6700(14) 
c/Å 26.187(4) 
α/° 90 
β/° 90.087(4) 
γ/° 90 
Volume/Å3 1890.8(5) 
Z 2 
ρcalcg/cm3 1.449 
μ/mm-1 0.215 
F(000) 860.9 
Crystal size/mm3 0.115 × 0.1 × 0.06 
Radiation Mo Kα (λ = 0.71073) 
2Θ range for data collection/° 4.5 to 52.98 
Index ranges 
-9 ≤ h ≤ 9, -12 ≤ k ≤ 12, -32 ≤ 
l ≤ 32 
Reflections collected 48450 
Independent reflections 7767 [Rint = 0.0550, Rsigma = 0.0423] 
Data/restraints/parameters 7767/49/508 
Goodness-of-fit on F2 1.038 
Final R indexes [I>=2σ (I)] R1 = 0.0559, wR2 = 0.1267 
Final R indexes [all data] R1 = 0.0633, wR2 = 0.1307 
Largest diff. peak/hole / e Å-3 0.42/-0.39 
Flack parameter 0.3(4) 
 
 
 
  
Table 4: Crystal data and structure refinement for EMT-bpe. 
Identification code EMT-bpe 
Empirical formula C28H30F2N8O6S2 
Formula weight 676.72 
Temperature/K 298.15 
Crystal system monoclinic 
Space group P21 
a/Å 7.4883(7) 
b/Å 11.2957(11) 
c/Å 18.1735(18) 
α/° 90 
β/° 100.406(5) 
γ/° 90 
Volume/Å3 1511.9(3) 
Z 2 
ρcalcg/cm3 1.486 
μ/mm-1 0.246 
F(000) 704.0 
Crystal size/mm3 0.145 × 0.065 × 0.03 
Radiation MoKα (λ = 0.71073) 
2Θ range for data collection/° 5.532 to 56.542 
Index ranges 
-9 ≤ h ≤ 9, -14 ≤ k ≤ 13, -24 ≤ 
l ≤ 17 
Reflections collected 12872 
Independent reflections 6094 [Rint = 0.0238, Rsigma = 0.0337] 
Data/restraints/parameters 6094/1/417 
Goodness-of-fit on F2 1.059 
Final R indexes [I>=2σ (I)] R1 = 0.0369, wR2 = 0.0838 
Final R indexes [all data] R1 = 0.0427, wR2 = 0.0869 
Largest diff. peak/hole / e Å-3 0.26/-0.19 
Flack parameter 0.04(2) 
 
 
  
 
Table 5: Crystal data and structure refinement for EMT-bpe 
Identification code EMT-bpeta 
Empirical formula C28H32F2N8O6S2 
Formula weight 678.73 
Temperature/K 296.15 
Crystal system monoclinic 
Space group P21 
a/Å 7.6333(8) 
b/Å 11.2359(11) 
c/Å 18.1058(18) 
α/° 90 
β/° 99.640(5) 
γ/° 90 
Volume/Å3 1531.0(3) 
Z 2 
ρcalcg/cm3 1.472 
μ/mm-1 0.243 
F(000) 708.0 
Crystal size/mm3 0.185 × 0.055 × 0.05 
Radiation MoKα (λ = 0.71073) 
2Θ range for data collection/° 5.512 to 49.994 
Index ranges 
-9 ≤ h ≤ 9, -13 ≤ k ≤ 13, -21 ≤ 
l ≤ 21 
Reflections collected 15295 
Independent reflections 5271 [Rint = 0.0313, Rsigma = 0.0339] 
Data/restraints/parameters 5271/1/446 
Goodness-of-fit on F2 1.024 
Final R indexes [I>=2σ (I)] R1 = 0.0292, wR2 = 0.0677 
Final R indexes [all data] R1 = 0.0325, wR2 = 0.0700 
Largest diff. peak/hole / e Å-3 0.14/-0.15 
Flack parameter 0.02(3) 
 
 
 
  
 
NMR Spectra 
 
Figure 11: 1H NMR spectra of EMT (300 MHz, DMSO-d6) 
 
 
 
 
  
Figure 12: 1H NMR spectra of EMT-apy (300 MHz, DMSO-d6) 
 
  
Figure 13: 1H NMR spectra of EMT-bpe (300 MHz, DMSO-d6) 
 
 
 
 
 
 
  
Figure 14: 1H NMR spectra of EMT-bpeta (300 MHz, DMSO-d6) 
 
 
 
 
 
 
 
 
 
 
 IR Spectra 
 
Figure 15: ATR-IR spectrum of (EMT)·(bpy) and starting materials. 
 
 
 
 
 
Figure 16: ATR-IR spectrum of (EMT)·(bpeta) and starting materials. 
 
  
Figure 17: ATR-IR spectrum of (EMT)·(bpe) and starting materials. 
 
 
 
 
 
 
Figure 18: ATR-IR spectrum of (EMT)·(azo) and starting materials. 
 
 
 
 
